Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Based on these types of analyses, Truven identified three major issues that payers are encountering with total population management as it relates to GLP-1 coverage: There remains significant improper use of GLP-1 medications
Its over-the-counter availability in lower doses makes it accessible to many patients
Current research in 2025 indicates that the overall benefits of GLP-1 medications for diabetes and cardiovascular health generally outweigh the eye risks for most patients
Genetic Factors Alteration of the Transsulfuration Pathway One of the classic alterations of the homocysteine metabolism is represented by the homozygous deficiency of CBS (Mudd et al, 1995)
US$ 22.45
US$ 28.62
US$ 26.31
US$ 28.77
